Theravance Biopharma, Inc. — Form 10-Q
Filed August 11, 2026 · analyzed by the Periodic Agent
10-Q
— Neutral
significance 28/100
What the filing says
Theravance Biopharma Ireland Limited offered severance to Áine Miller, effective 15 November 2026, comprising: €8,717 statutory redundancy payment, €433,835 ex-gratia termination payment, 12 months extended health insurance, outplacement counseling, and 24-month acceleration of time-based vesting on outstanding equity awards. Additionally, the company will contribute $250,000 USD to Miller's pension scheme. Total cash outlay approximately €442,500 plus $250,000 USD pension contribution. The letter dated 18 June 2026 was signed by CEO Rick E Winningham; Miller accepted on 19 June 2026.
Why this rating
Single executive departure with known severance costs (~$700K+ total, ~0.16% of $448.6M market cap). Routine redundancy; no indication of operational disruption or strategic impact.
See more from August 11, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.